Immuron sales reach $7.7 million in FY26

• Immuron (ASX:IMC) generated $7.7 million in global sales for FY26, representing a 6% increase over the prior year.
• Following the announcement, the Immuron share price remained unchanged at $0.043.
• The revenue increase was driven by strong sales of Travelan in Australia and steady expansion in North America.

Immuron (ASX:IMC) reported global sales of $7.7 million for FY26, marking a 6% increase over the prior comparative period.

The full-year result was supported by four consecutive quarters of year-over-year growth, contrasting with mixed performance across individual regional markets over the past 12 months.

"Immuron Limited is an Australian-based and globally integrated biopharmaceutical company pleased to announce continued sales growth of Travelan," said Immuron.

Domestic Australian sales led the full-year performance with $0.2 million.

Following the announcement, the Immuron share price was unchanged at $0.043.

The company's commercial portfolio relies primarily on Travelan, an over-the-counter immune supplement designed to target pathogenic bacteria and toxins in the gastrointestinal tract.

Alongside its commercial products, the business develops orally delivered targeted polyclonal antibodies, including clinical programmes targeting Clostridioides difficile infections and traveller's diarrhea.